Dr. Scott Rocklage attended the University of California, Berkeley where he earned a bachelor’s degree in chemistry. In 2003, Dr. Rocklage joined 5AM Venture as a partner. One year later, he became a managing partner. In 2005, he received Nobel peace prize in chemistry.
Dr. Scott Rocklage has been in the healthcare management for more than 30 years. He has submitted many medications to clinical trials. As an inventor, he has more than 30 U.S patents that he has either invented or co-invented. Additionally, Dr. Rocklage has assumed several leadership roles. He once was the Chairman as well as the CEO of the Cubist Pharmaceuticals. He was also the CEO and the President of Nycomed Salutar. Currently, he is the Board Chairman of Kinestral, Cidara, and Rennovia. Dr. Rocklage also works at the Massachusetts office of the 5AM Ventures.
Dr. Rocklage issued a press release on Expansion Therapeutics research stating that Mr. Disney will lead that scientific research. According to Dr. Disney, the work he has been able to complete together with the rest of the team for the past 12 years is what has made them be where they are today.
Apart from bringing the research team together, Dr. Rocklage with Expansion Therapeutic have plans that will bring advancement in the field of small molecules medicines that are targeting RNA. The team is keen on coming up with medications to help patients who do not have any other options. These medications depend on the science that can treat RNA-triggered illnesses. Myotonic dystrophy is one example of such a disease and is not treatable at the moment, but upon the successful outcome of the research results, this kind of condition will be treatable in future.
According to the statement of Kleiner Perkins Beth Seidenberg general partner, she was delighted together with her company to partner with a company that will make it possible to treat a disease that currently has no cure. Other partners in the undertaking are Sanofi Ventures, RA Capital Management, Alexandria Venture Investment, Novartis Venture Fund and 5AM Ventures, who took part in leading the financing.
Connect with Dr. Scott Rocklage on LinkedIn.